文献速递乳腺癌

当前辅助内分泌治疗试验NATALEE与monarchE选择标准对接受来曲唑初始治疗的绝经后HR阳性/HER2阴性乳腺癌患者的预后影响

Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
PubMed 文献 · Eur J Cancer · 2024-07-21

本研究基于PreFace试验中2891例绝经后HR阳性乳腺癌患者,按monarchE和NATALEE入组标准分组,评估iDFS和OS。384例(13.3%)符合monarchE主要标准,915/2886例(31.7%)符合NATALEE标准。monarchE≥4枚阳性淋巴结和NATALEE III期患者预后最差(3年iDFS率0.87),不符合试验标准者预后与符合标准中预后最好组相似。

要点

  • 2891例中384例(13.3%)符合monarchE主要标准,多数因≥4枚阳性淋巴结。
  • 2886例中915例(31.7%)符合NATALEE标准,其中126例(13.7%)淋巴结阴性。
  • monarchE≥4枚阳性淋巴结和NATALEE III期患者3年iDFS率0.87,预后最差。

核心结论

  • 符合monarchE和NATALEE试验的患者人群不同。
  • 近三分之一的既往接受来曲唑初始治疗的绝经后HR阳性人群符合NATALEE预后入选标准。
  • 由于某些符合标准组的预后与不符合标准患者相似,探索其他患者组接受CDK4/6i治疗可能是有意义的。

研究设计与样本

  • 研究采用历史患者队列,数据来自2009年至2011年入组辅助PreFace临床试验(NCT01908556)的患者。
  • 共3529例患者入组,纳入标准为绝经后激素受体阳性乳腺癌且适合五年来曲唑初始治疗。
  • 按monarchE和NATALEE入选标准将患者分为预后组,评估无侵袭性疾病生存(iDFS)和总生存(OS)。

主要发现

  • 2891例HR阳性患者中,384例(13.3%)符合monarchE主要入选标准,其中多数(n=261)因≥4枚阳性淋巴结而符合。
  • 2886例患者中915例(31.7%)符合NATALEE入选标准,其中126例(13.7%)为淋巴结阴性。
  • monarchE中≥4枚阳性淋巴结的患者和NATALEE中III期乳腺癌患者预后最差,3年iDFS率为0.87。
  • 不符合试验标准的患者预后与符合标准中预后最好的患者组相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The monarchE and NATALEE trials demonstrated the benefit of CDK4/6 inhibitor (CDK4/6i) therapy in adjuvant breast cancer (BC) treatment. Patient selection, based on clinical characteristics, delineated those at high (monarchE) and high/intermediate recurrence risk (NATALEE). This study employed a historical patient cohort to describe the proportion and prognosis of patients eligible for adjuvant CDK4/6i trials. METHODS: Between 2009 and 2011, 3529 patients were enrolled in the adjuvant PreFace clinical trial (NCT01908556). Eligibility criteria included postmenopausal patients with hormone receptor-positive (HRpos) BC for whom a five-year upfront therapy with letrozole was indicated. Patients were categorized into prognostic groups according to monarchE and NATALEE inclusion criteria, and their invasive disease-free survival (iDFS) and overall survival (OS) were assessed. RESULTS: Among 2891 HRpos patients, 384 (13.3 %) met the primary monarchE inclusion criteria. The majority (n = 261) qualified due to having ≥ 4 positive lymph nodes. For NATALEE, 915 out of 2886 patients (31.7 %) met the eligibility criteria, with 126 patients (13.7 %) being node-negative. Patients from monarchE with ≥ 4 positive lymph nodes and NATALEE with stage III BC exhibited the poorest prognosis (3-year iDFS rate 0.87). Patients ineligible for the trials demonstrated prognoses similar to the most favorable patient groups within the eligibility criteria. CONCLUSION: Patient populations eligible for monarchE and NATALEE trials differed. Nearly a third of the postmenopausal HRpos population, previously under upfront letrozole treatment, met the NATALEE prognostic eligibility criteria. As certain eligible groups had a prognosis similar to non-eligible patients, it might be interesting to explore additional patient groups for CDK4/6i therapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Fasching PA, Hack CC, Nabieva N, et al. Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole. Eur J Cancer. 2024. PMID: 39059184. doi:10.1016/j.ejca.2024.114239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。